PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1581-1588

  Tong, Yin ^a   Zhu, Weiwei ^a   Huang, Xianbo ^a   You, Liangshun ^a   Han, Xiujun ^b   Yang, Chunmei ^a   Qian, Wenbin ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

AKT; Apoptosis; Insulin like growth factor 1 receptor; MTOR; Multiple myeloma; Oncolysis; TRAIL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEATH RECEPTOR 5; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; ONCOLYTIC ADENOVIRUS; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIBIOTIC RESISTANCE; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMONES; ENZYME ACTIVATION; HUMANS; MORPHOLINES; MULTIPLE MYELOMA; ONCOGENE PROTEIN V-AKT; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PHOSPHATIDYLINOSITOL 3-KINASES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOR SERINE-THREONINE KINASES;

EID: 84908129327     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3020     Document Type: Article

References (45)

1. Kyle RA: Multiple myeloma: an odyssey of discovery. Br J Haematol 111: 1035-1044, 2000.
2. Brenner H, Gondos A and Pulte D: Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 94: 270-275, 2009.
3. Barlogie B, Attal M, Crowley J, et al: Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 28: 1209-1214, 2010.
4. Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937, 2002.
5. Hellwig CT and Rehm M: TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 11: 3-13, 2012.
6. Herbst RS, Eckhardt SG, Kurzrock R, et al: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28: 2839-2846, 2010.
7. Gajate C and Mollinedo F: Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109: 711-719, 2007.
8. Mitsiades CS, Treon SP, Mitsiades N, et al: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804, 2001.
9. Gazitt Y: TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13: 1817-1824, 1999.
10. Jazirehi AR, Ng CP, Gan XH, Schiller G and Bonavida B: Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res 7: 3874-3883, 2001.
11. Vitovski S, Chantry AD, Lawson MA and Croucher PI: Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. PLoS One 7: e35830, 2012.
12. Hermiston TW and Kuhn I: Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 9: 1022-1035, 2002.
13. Zhang ZL, Zou WG, Luo CX, et al: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13: 481-489, 2003.
14. Dong F, Wang L, Davis JJ, et al: Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-α-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 12: 5224-5230, 2006.
15. Pei Z, Chu L, Zou W, et al: An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39: 1371-1381, 2004.
16. Wang SB, Tan Y, Lei W, et al: Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect. Hum Gene Ther 23: 992-1002, 2012.
17. Meng H, Jin Y, Liu H, You L, Yang C, Yang X and Qian W: SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. J Hematol Oncol 6: 18, 2013.
18. Chauhan D, Velankar M, Brahmandam M, et al: A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26: 2374-2380, 2007.
19. Kuhn DJ, Berkova Z, Jones RJ, et al: Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120: 3260-3270, 2012.
20. Tagoug I, Sauty De Chalon A and Dumontet C: Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One 6: e22641, 2011.
21. Ikeda H, Hideshima T, Fulciniti M, et al: PI3K/p110δ is a novel therapeutic target in multiple myeloma. Blood 116: 1460-1468, 2010.
22. Maiso P, Liu Y, Morgan B, et al: Defining the role of TORC1/2 in multiple myeloma. Blood 118: 6860-6870, 2011.
23. Park S, Chapuis N, Tamburini J, et al: Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95: 819-828, 2010.
24. Oh WJ and Jacinto E: mTOR complex 2 signaling and functions. Cell Cycle 10: 2305-2316, 2011.
25. Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG and de Jong S: Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer 118: 1892-1900, 2006.
26. Seol DW: p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 416: 222-225, 2011.
27. Bais S, Bartee E, Rahman MM, McFadden G and Cogle CR: Oncolytic virotherapy for hematological malignancies. Adv Virol 2012: 186512, 2012.
28. Raus S, Coin S and Monsurrò V: Adenovirus as a new agent for multiple myeloma therapies: opportunities and restrictions. Korean J Hematol 46: 229-238, 2011.
29. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW and Russell SJ: Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26: 1870-1878, 2012.
30. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR and Barry MA: Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther 21: 179-190, 2010.
31. Chen CY, Senac JS, Weaver EA, et al: Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res 17: 6712-6722, 2011.
32. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999.
33. Tu Y, Gardner A and Lichtenstein A: The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 60: 6763-6770, 2000.
34. Hsu J, Shi Y, Krajewski S, et al: The AKT kinase is activated in multiple myeloma tumor cells. Blood 98: 2853-2855, 2001.
35. Bruno B, Giaccone L, Rotta M, Anderson K and Boccadoro M: Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 19: 1729-1738, 2005.
36. Sprynski AC, Hose D, Caillot L, et al: The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 113: 4614-4626, 2009.
37. Huo J, Xu S, Lin B, Chng WJ and Lam KP: Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma. Leukemia 27: 1165-1171, 2013.
38. Strömberg T, Ekman S, Girnita L, et al: IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107: 669-678, 2006.
39. Thaci B, Ulasov IV, Wainwright DA and Lesniak MS: The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2: 113-121, 2011.
40. Tamanini A, Nicolis E, Bonizzato A, Bezzerri V, Melotti P, Assael BM and Cabrini G: Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol 80: 11241-11254, 2006.
41. Verdino P, Witherden DA, Havran WL and Wilson IA: The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. Science 329: 1210-1214, 2010.
42. David E, Sinha R, Chen J, Sun SY, Kaufman JL and Lonial S: Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res 14: 5090-5098, 2008.
43. Surget S, Chiron D, Gomez-Bougie P, et al: Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 72: 4562-4573, 2012.
44. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G and Kruyt FA: TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 6: 2103-2112, 2007.
45. Mitsiades N, Poulaki V, Mitsiades C and Tsokos M: Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 61: 2704-2712, 2001.